Literature DB >> 6979235

Decrease in systolic blood pressure during exercise testing: reproducibility, response to coronary bypass surgery and prognostic significance.

D A Weiner, C H McCabe, S S Cutler, T J Ryan.   

Abstract

To investigate the reproducibility and prognostic significance of an exercise-induced decrease in systolic blood pressure, 47 patients were identified who manifested such a reduction below the pre-exercise standing level in a consecutive series of 436 patients who underwent treadmill exercise testing and cardiac catheterization during a 3 year period. The prevalence of this abnormal finding was 11 percent in the total group but 21 percent in the 124 patients with three vessel or left main coronary artery disease. Patients with an exercise-induced reduction in systolic blood pressure were more likely to be male, have typical angina pectoris with class III or IV functional limitation and to have had a prior myocardial infarction than were patients without this finding (p less than 0.05). Although no complications occurred during the exercise test of these 47 patients, the majority had severe ischemic responses and 14 (30 percent) showed complex repetitive ventricular arrhythmias. Of the 47 patients, 24 (group 1a) received medical treatment and 23 (group 1b) underwent coronary bypass surgery. On repeat exercise testing in 42 patients, a decrease in systolic blood pressure during exercise was consistently present in group 1a (17 of 20) but entirely absent (0 of 22) in group 1b (p less than 0.001). The mean treadmill time, peak heart rate and systolic blood pressure were not significantly different in the initial and on repeat exercise tests in patients in group 1a; however, in patients in group 1b, all of these variables were significantly higher in the repeat test (p less than 0.001). At a mean follow-up time of 37 months, the total cardiac mortality rate was 8 percent (2 of 24) in group 1a and 4 percent (1 of 23) in group 1b. It is concluded that a decrease in systolic blood pressure during exercise testing is highly reproducible and appears to be reversed by coronary bypass surgery.

Entities:  

Mesh:

Year:  1982        PMID: 6979235     DOI: 10.1016/0002-9149(82)90238-7

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

1.  Forearm vascular responses during semierect dynamic leg exercise in patients following myocardial infarction.

Authors:  H Thomson; J Morris-Thurgood; J Atherton; M P Frenneaux
Journal:  Heart Vessels       Date:  1998       Impact factor: 2.037

Review 2.  Noninvasive tests for diagnosing the presence and extent of coronary artery disease: exercise electrocardiography, thallium scintigraphy, and radionuclide ventriculography.

Authors:  L Goldman; T H Lee
Journal:  J Gen Intern Med       Date:  1986 Jul-Aug       Impact factor: 5.128

3.  Abnormal cardiovascular and catecholamine responses to supine exercise in human subjects with sympathetic dysfunction.

Authors:  G D Smith; L P Watson; D V Pavitt; C J Mathias
Journal:  J Physiol       Date:  1995-04-01       Impact factor: 5.182

4.  Post-exertion dizziness as the sole presenting symptom of autonomic failure.

Authors:  G D Smith; R Bannister; C J Mathias
Journal:  Br Heart J       Date:  1993-04

5.  Hemodynamic variables during stress testing can predict referral to early catheterization but failed to show a prognostic impact on emerging cardiac events in patients aged 70 years and older undergoing exercise (99m)Tc-sestamibi myocardial perfusion scintigraphy.

Authors:  Jan Bucerius; Alexius Y Joe; Ellen Herder; Holger Brockmann; Kim Biermann; Holger Palmedo; Klaus Tiemann; Hans-Jürgen Biersack
Journal:  Int J Cardiovasc Imaging       Date:  2009-04-21       Impact factor: 2.357

6.  Low but not high exercise systolic blood pressure is associated with long-term all-cause mortality.

Authors:  Kristofer Hedman; Leonard A Kaminsky; Ahmad Sabbahi; Ross Arena; Jonathan Myers
Journal:  BMJ Open Sport Exerc Med       Date:  2021-06-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.